Solstice Advanced Materials
Solstice Advanced Materials Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.9B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
24.9%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 2-year average)
★★☆☆☆position among all companies
3.2%
Capital efficiency
★★★★☆position among all companies
16.8%
Revenue and profit
Performance, financial position and capital allocation
Solstice Advanced Materials
Recent performance trends
Solstice Advanced Materials
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | Could not be retrieved | Could not be retrieved | US$3.6 billion | US$3.8 billion | US$3.9 billion |
| Net income | Could not be retrieved | Could not be retrieved | US$0.6 billion | US$0.6 billion | US$0.2 billion |
| Total assets | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$5.0 billion | US$5.7 billion |
| Shareholders' equity | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$3.3 billion | US$1.4 billion |
| Net cash provided by (used in) operating activities | Could not be retrieved | Could not be retrieved | US$0.8 billion | US$0.8 billion | US$0.5 billion |
| Net cash provided by (used in) investing activities | Could not be retrieved | Could not be retrieved | US$-0.3 billion | US$-0.3 billion | US$-0.3 billion |
| Net cash provided by (used in) financing activities | Could not be retrieved | Could not be retrieved | US$-0.4 billion | US$-0.5 billion | US$-0.2 billion |
| Cash and cash equivalents | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$0.7 billion | US$0.5 billion |
Revenue scale in the same industry
Solstice Advanced Materials
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 42 companies
- 46 Jazz PharmaceuticalsFY Dec 2025 US$4.3B
- 47 Union CarbideFY Dec 2025 US$4.0B
- 48 Solstice Advanced MaterialsThis companyFY Dec 2025 US$3.9B
- 49 Alnylam PharmaceuticalsFY Dec 2025 US$3.7B
- 50 CabotFY Sep 2025 US$3.7B
- … 6 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.3 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.5 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$24.00 million | Consolidated | Disclosed |
| Dividends paid | US$1.5 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$1.4 billion | Consolidated | Disclosed |
| Non-controlling interests | US$-34.00 million | Consolidated | Disclosed |
| Net assets | US$1.4 billion | Consolidated | Disclosed |
| Net sales | US$3.9 billion | Consolidated | Disclosed |
| Net income | US$0.2 billion | Consolidated | Disclosed |
| Total assets | US$5.7 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 24.9% | Consolidated | Calculated |
| Net margin | 6.1% | Consolidated | Calculated |
| Return on equity | 16.8% | Consolidated | Calculated |